Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + Lenalidomide for MM Consolidation/Maintenance
NCT05820763Phase 2Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of selinexor in multiple myeloma (MM), myeloma-associated amyloidosis, sponsored by Washington University School of Medicine. Planned start Jan 2024; status: withdrawn.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)myeloma-associated amyloidosis
Beyond the preview
Go deeper on NCT05820763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05820763.